Comparative Pharmacology
Head-to-head clinical analysis: DEXFERRUM versus FERAHEME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXFERRUM versus FERAHEME.
DEXFERRUM vs FERAHEME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iron replacement therapy; provides iron for hemoglobin synthesis and erythropoiesis in iron-deficiency states.
Ferumoxytol is a superparamagnetic iron oxide nanoparticle coated with a semisynthetic carbohydrate shell. It serves as a source of iron for hemoglobin synthesis and replenishes iron stores. The iron core is processed intracellularly to release iron, which is then incorporated into hemoglobin or stored as ferritin. The carbohydrate shell is metabolized and eliminated.
100 mg intravenously over 2-5 minutes; may repeat if indicated (total dose depends on iron deficit).
510 mg intravenously once, followed by a second 510 mg dose 3 to 8 days later, not exceeding 1020 mg per course.
None Documented
None Documented
Terminal elimination half-life: 2.3–3.5 hours in adults with normal renal function. Closely follows iron kinetics; clinical effect persists beyond half-life due to intracellular iron utilization.
Terminal half-life of ferumoxytol (iron core) is approximately 14-21 hours; for the intact nanoparticle (carbohydrate shell), half-life is about 15 hours. Clinically, iron is continuously released and incorporated, extending effects beyond half-life.
Primarily renal: ~60% as intact drug; ~20% as metabolites. Biliary/fecal: ~15% as metabolites. Unchanged drug in feces <5%.
Renal: minimal (<1% as intact drug); primarily degraded endogenously with iron incorporated into hemoglobin; fecal/biliary elimination of unabsorbed iron is negligible.
Category C
Category C
Iron Supplement
Iron Supplement